Glaucoma is a group of eye disorders traditionally
characterized by progressive damage to the eye, at
least partly due to elevated intraocular pressure (IOP).
Glaucoma affects 1 in 200 people aged 50 or younger
and 1 in 10 over the age of 80. It is the leading
cause of irreversible blindness in the world and the
second leading cause of vision loss after cataract,
which is reversible surgically. Primary open-angle
glaucoma (POAG) is the most common form of glaucoma,
accounting for about 60 to 70% of all glaucoma.
Latanoprost is being used alone or in combination
with other agents for the treatment of glaucoma. The
rationale for the development of a topical ocular
product that combines a prostaglandin analogue (Latanoprost)
and a s-blocker (Timolol) in a single formulation
was to provide a better product with IOP-lowering
efficacy that is greater than either component
product alone, IOP-lowering efficacy that is similar
to the concomitant administration of the component
products, and convenience of once-daily dosing,
thereby promoting better compliance.
1. Ishida N, Odani-Kawabata N, Shimazaki A,;
Prostanoids in the therapy of glaucoma; Cardiovasc
Drug Rev. 2006 Spring;24(1):1-10. Review.
2. Detry-Morel M.; Side effects of glaucoma
medications; Bull Soc Belge Ophtalmol.
2006;(299):27-40. Review.
3. Holmstrom S, Buchholz P, Walt J, Wickstrom J,
Aagren M.; Analytic review of bimatoprost,
latanoprost and travoprost in primary open angle
glaucoma; Curr Med Res Opin. 2005
Nov;21(11):1875-83. Review.
4. Grierson I, Jonsson M, Cracknell K.; Latanoprost
and pigmentation; Jpn J Ophthalmol. 2004
Nov-Dec;48(6):602- 12. Review.
5. Feldman RM.; An evaluation of the
fixed-combination of latanoprost and timolol for use
in open-angle glaucoma and ocular hypertension;
Expert Opin Pharmacother. 2004 Apr;5(4):909-21.
Review.
6. Fechtner RD, Realini T.; Fixed combinations of
topical glaucoma medications; Curr Opin Ophthalmol.
2004 Apr;15(2):132-5. Review.
7. Costagliola C, Parmeggiani F, Sebastiani A.;
Assessing the cost-effectiveness of switching from a
beta-blocker to latanoprost in the treatment of
ocular hypertension; Expert Opin Pharmacother. 2003
Oct;4(10):1775-88. Review.
8. Brubaker RF.; Targeting outflow facility in
glaucoma management; Surv Ophthalmol. 2003 Apr;48
Suppl 1:S17- 20. Review.
9. Perry CM, McGavin JK, Culy CR, Ibbotson T.;
Latanoprost : an update of its use in glaucoma and
ocular hypertension; Drugs Aging.
2003;20(8):597-630. Review.
10. Johnstone MA, Albert DM.; Prostaglandin-induced
hair growth; Surv Ophthalmol. 2002 Aug;47 Suppl
1:S185-202. Review.
11. Grierson I, Pfeiffer N, Cracknell KP, Appleton
P.; Histology and fine structure of the iris and
outflow system following latanoprost therapy; Surv
Ophthalmol. 2002 Aug;47 Suppl 1:S176-84. Review